Motegrity Interactions
There are 108 drugs known to interact with Motegrity (prucalopride), along with 4 disease interactions. Of the total drug interactions, 47 are moderate, and 61 are minor.
- View all 108 medications that may interact with Motegrity
- View Motegrity disease interactions (4)
Most frequently checked interactions
View interaction reports for Motegrity (prucalopride) and the medicines listed below.
- albuterol
- amitriptyline
- aspirin
- atorvastatin
- baclofen
- clonazepam
- cyclobenzaprine
- famotidine
- gabapentin
- hydroxyzine
- levothyroxine
- Linzess (linaclotide)
- Lyrica (pregabalin)
- magnesium oxide
- melatonin
- metformin
- MiraLAX (polyethylene glycol 3350)
- montelukast
- omeprazole
- ondansetron
- pantoprazole
- prednisone
- promethazine
- propranolol
- trazodone
- Trulance (plecanatide)
- Vitamin B12 (cyanocobalamin)
- Vitamin D3 (cholecalciferol)
- Zofran (ondansetron)
- Zyrtec (cetirizine)
Motegrity disease interactions
There are 4 disease interactions with Motegrity (prucalopride) which include:
Report options
QR code containing a link to this page
More about Motegrity (prucalopride)
- Motegrity consumer information
- Compare alternatives
- Pricing & coupons
- Reviews (66)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: serotoninergic neuroenteric modulators
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
